AcelRx Pharmaceuticals (ACRX), La Jolla Pharmaceutical Company (LJPC) & Melinta Therapeutics (MLNT) takeover of TetraPhase Pharmaceuticals (TTPH) information is displayed in the merger details tables below. An invaluable buyout factsheet for traders and investors looking to trade the merger arbitrage spread.
As this acquisition is the subject of a bidding war, we strongly recommend traders read all necessary documents carefully to obtain and fully understand the deal specifics (which may not necessarily referred to here) before initiating a stock position.
This deal was successfully consummated on July 28, 2020
TetraPhase Pharmaceuticals (TTPH) Acquisition
Receive instant FREE access to constantly updated TTPH news related to the current takeover deal. Simply register by entering your email address to receive weekly publication updates. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, click TetraPhase Pharmaceuticals (TTPH). Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box such as “TTPH“, or clicking on a stock ticker in the tag cloud at the foot of this article.
Traders and shareholders can review similar deal information on current merger stocks by first selecting “DEALS” from the main menu, then “Current Cash Deals” or “Current Stock Deals“. For previous acquisitions, select either “Closed Deals” or “Failed Deals“. Broader mergers and acquisitions news on other constituents of the T20 portfolio, please see our Spread Tracker News feed.
TetraPhase Pharmaceuticals (NASDAQ: TTPH) Acquisition - Merger News and Events
The major acquisition news updates & events of TetraPhase Pharmaceuticals (TTPH) by either AcelRx Pharmaceuticals (ACRX), La Jolla Pharmaceutical Company (LJPC) or Melinta Therapeutics (MLNT) are listed below. A comprehensive data source for traders & investors looking to familiarize themselves with the TetraPhase Pharmaceuticals (TTPH) buyout and trade the merger arbitrage spread, or for existing shareholders wishing to stay abreast of the latest deal developments. Following the acquisition news and events section, there is an in-depth company profile.
TetraPhase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company’s lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI.
It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
